CAPITOL WEEKLY PODCAST: Today we present a Special Episode of the Capitol Weekly Podcast, recorded live, Thursday May 26 at CALIFORNIA VOTES, A 2022 Election Preview. Panelists Kathy Fairbanks and David Miller discuss the merits of the proposition, moderated by Sigrid Bathen of Capitol Weekly.
A liquid nitrogen bank containing a suspension of stem cells for biomedical research. (Photo: Elena Pavlovich, via Shutterstock)California is planning on spending $49,000 an hour, 24 hours a day, seven days a week during the next year to help scientists develop what some describe as “miraculous” cures and treatments for currently deadly afflictions. The spending plan was approved with no fuss last month while state lawmakers and the governor wrestled more noisily with a $308 billion state budget
A research scientist examines a capsule with a DNA double helix. (Photo: Dan Race, via Shutterstock)One year ago this month, a $5.5 billion wave washed over California’s ambitious stem cell agency and left it refreshed and renewed for another decade or so of searching for “miraculous” treatments for a host of deadly, incurable afflictions. It is now on a pace to hand out $38,000 an hour, 24 hours a day, seven days a week. That would amount to $519 million in awards between this time last year and the end of the agency’s current fiscal year in June.
A laboratory researcher examines cancer stem cells. (Image: science photo, via Shutterstock)Backers of a $5.5 billion stem cell research proposal in California today have once again missed a self-imposed, but critical deadline as they continue to struggle with securing enough signatures to place the measure on the November ballot.
A voter signs a petition to place a measure on the statewide ballot. (Photo: Svineyard, via Shutterstock)It’s never easy to get initiatives qualified for the ballot, but this year of the COVID-19 pandemic is the worst ever. Organizations busily trying to get enough signatures to qualify their measure of choice had their efforts abruptly halted two weeks ago because of Gov. Gavin Newsom’s sweeping stay-at-home order.
A laboratory stem cell researcher uses a laptop in conjunction with a microscope. (Photo: moreimages, via Shutterstock)A small firm in Menlo Park, Ca., is probably the only company in the nation that is named after the number of a particular human protein. It is a small number too, only 47. But it has large implications for California’s financially strapped state stem cell agency.
A pipette and vessels usd in stem cell research. (Photo: CI Photos, via Shutterstock)The price tag for refinancing California’s unique and ambitious stem cell research program could run to close to $7.8 billion, give or take a few hundred million dollars or more. So says the state’s legislative analyst in a financial analysis of a proposed ballot initiative that is likely to be on next November’s ballot.
A scientist examines cells in a biological laboratory. (Photo: anyalvanova, via Shutterstock)The man expected to lead the drive for $5.5 billion more for California’s stem cell agency today said the Trump restrictions on fetal tissue research represent a dangerous precedent that threatens the health of all Americans.
Blood cells in a bone marrow smear, examined as part of stem cell research. (Photo: toeytoey, via Shutterstock)California’s state stem cell agency is down to its last $67.3 million following a decision Thursday to back research to enhance bone healing in elderly patients who undergo spinal surgery. The $4 million award went to Ankasa Regenerative Therapeutics following little discussion among members of the governing board of the $3 billion California Institute for Regenerative Medicine.
Human fetal placenta under high magnification. (Photo: photowind, via ShutterstockThe California stem cell agency says the Trump administration’s moves against research involving fetal tissue have had no impact on the projects that it is financing, at least so far. The agency, formally known as the California Institute for Regenerative Medicine (CIRM), was responding to a question originally raised by a reader of the California Stem Cell Report.